Form 4: Krystal Biotech CEO Sells Shares via 10b5-1 Plan

Krystal Biotech's President and CEO, Krish S. Krishnan, and his spouse reported sales and a gift of company common stock totaling 55,000 shares.

Summary

• Krish S. Krishnan, President and CEO of Krystal Biotech, Inc., reported direct sales of 25,000 shares of common stock on December 4, 2025, at weighted average prices ranging from $214.2797 to $222.1986.
• These sales were executed under a Rule 10b5-1 trading plan adopted on September 4, 2025, which is set to terminate on December 4, 2026, or earlier upon completion of the maximum number of shares subject to the plan.
• Krish S. Krishnan also made a bona fide gift of 5,000 shares of common stock to a charitable donor-advised fund on December 5, 2025, with a transaction price of $0.
• Suma M. Krishnan, the spouse of the Reporting Person, reported sales of 25,000 shares of common stock on December 4, 2025, at weighted average prices ranging from $214.2503 to $222.375.
• These sales by the spouse were also conducted under a Rule 10b5-1 trading plan adopted on September 4, 2025, with the same termination conditions as the CEO's plan.
• Following these transactions, Krish S. Krishnan directly beneficially owns 1,478,056 shares and indirectly owns 90,000 shares via the Krishnan Spousal Trust, 50,000 shares via the Krishnan Family Trust, and 1,413,711 shares indirectly through his spouse.

Sentiment

Score: 4

Explanation: The filing reports significant insider selling by the CEO and his spouse. While these sales were conducted under pre-arranged 10b5-1 plans, which reduces the implication of opportunistic selling, a reduction in insider ownership can still be viewed with slight caution by investors. The charitable gift is a neutral to positive factor.

Positives

• The transactions were executed under pre-arranged Rule 10b5-1 trading plans, indicating planned sales rather than opportunistic selling based on new, undisclosed information.
• A portion of the shares (5,000) was a bona fide gift to a charitable donor-advised fund, which is a philanthropic act.

Negatives

• The President and CEO, Krish S. Krishnan, and his spouse collectively disposed of 55,000 shares of Krystal Biotech common stock.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

The Rule 10b5-1 trading plans adopted by Krish S. Krishnan and his spouse are set to continue until December 4, 2026, or until the maximum number of shares subject to the plans have been sold.

Management Comments

• The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025.
• The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan.
• Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund.

Industry Context

This insider transaction report reflects a common practice among executives in high-growth sectors like biotechnology to diversify their personal holdings through pre-arranged trading plans, rather than indicating a direct correlation to broader industry trends.

Related Party Transactions

• Sales of common stock by Suma M. Krishnan, spouse of the Reporting Person, under a separate Rule 10b5-1 plan.
• Beneficial ownership of 90,000 shares by Krishnan Spousal Trust.
• Beneficial ownership of 50,000 shares by Krishnan Family Trust, where the Reporting Person and spouse are joint beneficial owners with joint voting and investment control.

Stakeholder Impact

• Shareholders may view the insider selling with slight caution, though the execution under a 10b5-1 plan mitigates concerns about opportunistic timing. The reduction in direct insider ownership could be a minor point of consideration.

Next Steps

• The Rule 10b5-1 trading plans adopted by Krish S. Krishnan and his spouse will continue until December 4, 2026, or until the maximum number of shares subject to the plans have been sold.

Key Dates

Recommendation

While the CEO and his spouse have sold a notable number of shares, these transactions were executed under pre-established 10b5-1 plans, which suggests a planned diversification or liquidity event rather than a reaction to new negative company-specific news. The remaining beneficial ownership is still substantial. Without additional information on the company's fundamentals or future prospects, this Form 4 alone does not warrant a 'sell' recommendation, but the insider selling prevents a 'buy' recommendation. Investors should 'hold' and monitor future company performance and insider activity.

Keywords

Krystal Biotech, KRYS, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, CEO, Beneficial Ownership, Equity Transaction, Biotech